Involvement of TIRAP/MAL in signaling for the activation of interferon regulatory factor 3 by lipopolysaccharide  by Shinobu, Noriaki et al.
Involvement of TIRAP/MAL in signaling for the activation of interferon
regulatory factor 3 by lipopolysaccharide
Noriaki Shinobua;1, Tomokatsu Iwamuraa;1, Mitsutoshi Yoneyamaa, Kazumi Yamaguchia,
Wakako Suharaa, Yukiko Fukuharaa, Fumio Amanob;2, Takashi Fujitaa;
aDepartment of Tumor Cell Biology, The Tokyo Metropolitan Institute of Medical Science, 3-18-22 Honkomagome, Bunkyo-ku,
Tokyo 113-8613, Japan
bDepartment of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
Received 7 March 2002; accepted 22 March 2002
First published online 4 April 2002
Edited by Masayuki Miyasaka
Abstract Infections of bacteria and viruses induce host defense
reactions known as innate responses that include the produc-
tion of cytokines and chemokines. The production of type I
interferon (IFN) is known to be induced by viral double-stranded
(ds) RNA or bacterial lipopolysaccharide (LPS). Although
important functions for the transcription factors NF-UB and
interferon regulatory factor-3 (IRF-3) are indicated, the
molecular signals leading to the activation of IFN genes have
yet to be elucidated. We provide several lines of evidence that
LPS and dsRNA trigger distinct intracellular signals upstream.
Notably, our investigation revealed a critical function for
TIRAP/MAL, a signaling adapter for Toll-like receptor (TLR)
4, in LPS-induced but not dsRNA-induced activation of IRF-3.
These results highlight cross-talk between TLR-mediated and
virus/dsRNA-induced signals resulting in activation of the IFN
system. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Infections by microorganisms provoke a series of responses,
known as innate immunity, through the recognition of com-
ponents of pathogens [1,2]. The framework of these responses
is conserved from Caenorhabditis elegans through insects to
mammals. Pathogen-derived molecules or pathogen-associ-
ated molecular patterns are recognized by transmembrane re-
ceptors, Toll or Toll-like receptor (TLR), then the signals are
transduced to cytoplasm [1,3]. It is well established that the
signal generated by lipopolysaccharide (LPS)/TLR4 interac-
tion is transmitted to adapter molecules, MyD88, IRAK
and TRAF6, and this event is followed by the triggering of
an IUB kinase (IKK) and mitogen-activated protein (MAP)
kinase cascade resulting in the activation of transcription fac-
tors NF-UB, AP-1 and ATF-2 [1]. These transcription factors
play crucial roles in inducing the expression of genes including
those of various chemokines and cytokines which activate
host defense against these pathogens.
The type I interferon (IFN) system is known to function
against a broad spectrum of viral infections [4,5]. Production
of type I IFN is induced at the level of transcription by in-
fections of various types of RNA and DNA viruses [4]. Type I
IFN gene induction by virus/double-stranded (ds) RNA in-
volves the activation of transcription factors NF-UB and
ATF-2/c-Jun [6,7], however these factors alone are not re-
sponsible for the gene expression, since they can be activated
by non-viral stimuli without signi¢cant expression of the IFN
genes. Recently, the involvement of IFN regulatory factor
(IRF)-3 and IRF-7 in the viral induction of IFN genes was
demonstrated [7,8]. IRF-3 in particular plays a key role in the
induction. IRF-3 is ubiquitously expressed and accumulated
in the cytoplasm in its inactive form. Viral infection or treat-
ment with dsRNA activates cellular kinase which phosphor-
ylates IRF-3 at speci¢c serine residues resulting in a dimeric
IRF-3 [7^9]. The IRF-3 dimer then complexes with the co-
activator, CREB binding protein (CBP) or p300, to form a
DNA binding-competent holocomplex in the nucleus [9].
In addition to virus or dsRNA, LPS can induce production
of IFN in certain cells, albeit usually at low levels [10,11].
Activation of IRF-3 by LPS treatment was initially docu-
mented in the human astrocyte cell line U373 [12]. Further-
more, treatment of mouse macrophages with LPS results in
the activation of IRF-3 in a MyD88-independent manner [13].
In the present study, we compared the mechanism of IRF-3
activation induced by LPS and dsRNA. We found several
lines of evidence indicating that LPS and dsRNA stimulate
distinct signal pathways and the signals are integrated down-
stream to direct a common pathway leading to the activation
of IRF-3 and NF-UB. Moreover, our results with wild-type
and dominant negative TIRAP/MAL [14,15], an alternative
adapter to MyD88 for TLR4-mediated signaling, strongly
suggest that Toll-interleukin 1 receptor (TIR) domain-con-
taining adapter protein/MyD88 adapter like (TIRAP/MAL)
plays a critical role in the LPS-induced activation of IRF-3.
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2. Materials and methods
2.1. Cell culture and transfection
U373 and L929 cells were cultured as described [8,12]. DNA trans-
fection of U373 cells was performed by using TransIT-LT1 reagent
(PanVera).
2.2. Plasmid constructs
All mammalian expression constructs for human IRF-3 have been
described previously [9]. pRLTK containing the Renilla luciferase
gene driven by a herpes simplex virus thymidine kinase promoter
was obtained from Promega. p-55A2RL, p-55UASGLuc and pEF-
Gal4/IRF-3 have been described elsewhere [16]. Human TIRAP/
MAL cDNA was isolated by PCR ampli¢cation of U373 cDNA.
The ampli¢ed fragment was subcloned into pEF-BOS [17] to generate
pEF-TIRAP. The construct pEF-TIRAP-P125H was made by Gene
editor (Promega).
2.3. Antibodies, cytokines and reagents
Antibodies to human IRF-3 (NES), p50 Tag and IRF-9 have been
described previously [8,9]. Antibodies to p300 and CBP were from
Santa Cruz Biotechnology. Phospho-speci¢c antibodies to p38 and
SAPK/JNK were from Cell Signaling Technology. Sources of reagents
were: LPS from Salmonella minnesota Re595, Tilorone, Tilorone 874
and acridine orange (Sigma); poly(I:C) (Amersham Pharmacia); re-
combinant human interleukin-1 (IL-1) and tumor necrosis factor-K
(TNF-K) (Genzyme); PD98059, staurosporine, hypericin, calphostin,
SB202190, N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) and
NK-p-tosyl-L-lysine chloromethyl ketone (TLCK) (Calbiochem); gel-
danamycin (Gibco-BRL).
2.4. Native PAGE, EMSA and luciferase assay
The native polyacrylamide gel electrophoresis (PAGE) assay has
been described previously [16]. Electrophoretic mobility shift assay
(EMSA) was performed as described previously [8]. Fire£y and
Renilla luciferase activities were determined using a Dual-Luciferase
Reporter assay system (Promega).
3. Results
3.1. Activation of IRF-3 induced by bacterial LPS
To con¢rm the results from another laboratory [12], we
subjected U373 cells, which had been treated with LPS, to
conventional assays for IRF-3 activation. However, the acti-
vation of IRF-3 was below the detectable level. Therefore we
performed a more sensitive assay based on native PAGE [16].
The active holocomplex of IRF-3 is composed of a stable
IRF-3 dimer and CBP/p300, which is reversibly dissociated
in the presence of 1% deoxycholate [9]. The basis of this assay
is to detect the stable IRF-3 dimer resulting from speci¢c
serine phosphorylation. In unstimulated U373 cells, IRF-3
was detected as a single, fast migrating band (Fig. 1A, lane
1, IRF-3 monomer). When cells were stimulated with
poly(I:C) for 1 h, a slowly migrating band was generated
(lane 3) along with a moderate induction of NF-UB (lower
panel). As reported earlier, this band corresponds to the ho-
modimer of IRF-3 [16]. When the cells were treated with LPS
for 2 h, a weak but clear formation of IRF-3 homodimer was
detected (lane 2). TNF-K, a strong inducer of NF-UB, did not
signi¢cantly induce IRF-3 activation (lane 4). The time course
experiment (Fig. 1B) shows that the activation of IRF-3 by
LPS occurred as early as 1 h and culminated at 2 h and
decreased thereafter. With the native PAGE assay, we con-
¢rmed that LPS treatment results in the activation of IRF-3 in
the mouse macrophage cell line JA-4 but not in LPS1916, a
mutant of JA-4 whose ability to respond to LPS is signi¢-
cantly impaired, [18] (data not shown). Furthermore, we con-
¢rmed the involvement of TLR4 in the signaling for the acti-
vation of IRF-3 by using peritoneum macrophages derived
from C3H/HeJ Mice [19] (data not shown).
3.2. Characterization of IRF-3 holocomplex induced by LPS
During initial characterization of U373 cells, we found that
ectopic expression of CD14 markedly augmented sensitivity to
LPS and lipoteichoic acid. Therefore we used U373 cells sta-
bly expressing CD14 (U373/CD14), which exhibited one order
of magnitude higher induction of IFN-L and IP10 chemokine
genes in response to LPS (data not shown). We examined the
molecular nature of the IRF-3 activated by dsRNA or LPS
(Fig. 2A). When U373/CD14 was treated with LPS for 1 h, an
apparent IFN-stimulated response element (ISRE) binding
activity was observed (lane 3), which exhibited identical mo-
bility to the poly(I:C)-induced IRF-3 holocomplex (lane 2). A
supershift/blocking experiment clearly showed that the com-
plex contained IRF-3 (lane 5) but not IRF-9 (lane 4). Under
these conditions, IFN-stimulated gene factor 3 is detectable as
late as 2 h (data not shown). Another hallmark of the activa-
tion of IRF-3 by virus/dsRNA is its association with co-acti-
vator CBP/p300, which is needed to expose the DNA binding
activity of IRF-3 [9]. Antibodies to p300 and CBP, particu-
larly the latter, inhibited the formation of the complex, indi-
cating that the formation of a holocomplex similar to that
induced by poly(I:C) treatment was induced by LPS (lanes
6^8).
It has been suggested that the serine residues at positions
385 and 386 are critical targets for the virus/dsRNA-induced
Fig. 1. A: Activation of IRF-3 in U373 cells induced by dsRNA and LPS. U373 cells were mock-treated (lane 1) or treated with LPS (lane 2,
5 Wg/ml for 2 h), poly(I:C) (lane 3, 20 Wg/ml for 1 h), or TNF-K (lane 4, 10 ng/ml for 1 h). The extracts were subjected to native PAGE assay
for IRF-3 (upper panel) using anti-hNES or EMSA for NF-UB (lower panel). Bands corresponding to the monomer of IRF-3, dimer of IRF-3
and NF-UB are indicated. B: Kinetics of IRF-3 activation induced by LPS. U373 cells were mock-treated (lane 1) or treated with 5 Wg/ml LPS
(lane 2) for the periods indicated. Cell extracts were subjected to native PAGE assay for IRF-3.
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phosphorylation [8]. To investigate the importance of these
residues to the LPS-induced activation of IRF-3, epitope-
tagged IRF-3 with either wild-type or mutant S385A or
S386A was expressed in U373 cells together with CD14. The
cells were treated with LPS and cell lysates were subjected to
native PAGE assay using the tag-speci¢c antibody. Fig. 2B
shows that dimer formation of wild-type IRF-3 was clearly
induced by LPS (lane 4), however the mutants with a substi-
tution of either of the critical serine residues did not respond
to the induction by LPS (lanes 5^8). The result suggested that
the signal induced by LPS and virus/dsRNA results in a sim-
ilar modi¢cation on the IRF-3 molecule, most likely by phos-
phorylation of these serine residues.
3.3. Distinct signal pathways induced by LPS and dsRNA
Next, the intracellular signal cascade was analyzed by the
use of metabolic inhibitors and native PAGE analysis for
IRF-3. Staurosporine and TPCK but not TLCK blocked
the activation of IRF-3 induced by LPS or poly(I:C) (Fig.
3A). However, SB202190 and PD98059, inhibitors for p38
and MAPKK, respectively, did not a¡ect the activation of
IRF-3. Calphostin and hypericin selectively blocked the acti-
vation of NF-UB. Tilorone, tilorone 874, acridine orange and
geldanamycin blocked the activation of IRF-3 induced by
poly(I:C) but not by LPS (Fig. 3B,C), indicating distinct sig-
naling pathways are activated by these stimuli.
3.4. p38 and SAPK/JNK are not su⁄cient to activate IRF-3
IL-1 triggers signal through its cognate receptor and
transduces it to MyD88, IRAK and TRAF6, as TLR4
does [1]. The results in Fig. 4A demonstrate that LPS, IL-1
and poly(I:C) activated the NF-UB, p38 and SAPK/JNK
pathways to virtually the same extent (lanes 1^4). How-
ever, the activation of IRF-3 was exclusively observed in
cells stimulated with LPS or poly(I:C) (lanes 2 and 4).
Moreover, UV irradiation, which strongly activates p38
and SAPK/JNK, induced neither IRF-3 homodimer (lanes
5^7) nor IRF-3 DNA binding activity (B). UV irradiation
resulted in a change of mobility of IRF-3 in SDS^PAGE
(C), presumably due to N-terminal phosphorylation by
MAPKKK-related signal [20]. These results strongly suggest
that activation of p38 and SAPK/JNK is not su⁄cient to
activate IRF-3.
3.5. TIRAP/MAL is involved in LPS-induced activation of
IRF-3
Recently, a molecule containing a TIR domain termed TI-
RAP or MAL was identi¢ed [14,15]. Overexpression of wild-
type TIRAP/MAL results in the activation of NF-UB. More-
over, overexpression of TIRAP/MAL with a single amino acid
substitution (P125H) dominantly blocks the activation, indi-
cating that TIRAP/MAL is a critical adapter for TLR4-medi-
ated signaling [14,15]. We investigated the function of TIRAP/
MAL in the activation of IRF-3 by LPS. To address specif-
ically the activation of IRF-3, the reporter system using Gal4/
IRF-3 was employed [16](Fig. 5). LPS stimulation resulted in
the activation of Gal4/IRF-3 fusion protein in U373 cells
(A, Vector). Overexpression of wild-type TIRAP/MAL re-
sulted in the constitutive activation of Gal4/IRF-3 and stim-
ulation by LPS augmented this activation (A, TIRAP). The
level of constitutive activity was proportional to the amount
of TIRAP expression vector (B). Under these conditions,
overexpression of wild-type TIRAP/MAL induced dimeriza-
tion of endogenous IRF-3, as analyzed by native PAGE assay
(C). Conversely, the mutant P125H not only failed to activate
the reporter but dominantly inhibited the gene induction by
Fig. 2. A: Analysis of ISRE DNA binding activity induced by LPS. U373/CD14 cells were mock-treated (lane 1) or treated with poly(I:C)
(lane 2) or with LPS (5 Wg/ml) for 1 h (lanes 3^8). The cell extracts were subjected to EMSA using ISG15 probe in the absence (lanes 1^3) or
presence of antibodies (anti-IRF-9, lane 4; anti-IRF-3, lane 5; anti-p300, lane 6; anti-CBP, lane 7; anti-p300 and anti-CBP, lane 8). Arrow in-
dicates IRF-3 holocomplex. B: Involvement of Ser385 and Ser386 in the LPS-induced activation of IRF-3. U373 cells (2U105 cells in a 3.5 cm
dish) were transiently transfected with 2.5 Wg of control vector pEF-BOS (lanes 1 and 2) or expression vector for p50-tagged wild-type hIRF-3
(lanes 3 and 4), hIRF-3/S385A (lanes 5 and 6) or hIRF-3/S386A (lanes 7 and 8), and 2.5 Wg of expression vector for CD14 (lanes 1^8). The
cells were mock-treated (lanes 1, 3, 5, and 7) or treated with LPS (5 Wg/ml) (lanes 2, 4, 6, and 8) for 2 h. The cell extracts were subjected to
native PAGE assay for tagged IRF-3.
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LPS (A, TIRAP-P125H) in a dose-dependent manner (D).
These results strongly suggest a crucial role for TIRAP/
MAL in the LPS-induced activation of IRF-3. Poly(I:C)
also induced the reporter expression and additively augmented
the constitutive activity induced by TIRAP/MAL (E). How-
ever, the expression of TIRAP/P125H did not inhibit the
poly(I:C)-induced gene expression (E, TIRAP/P125H). With
mouse L929 cells, neither a constitutive activation by TIRAP/
MAL nor a dominant negative e¡ect of TIRAP-P125H was
observed (F).
Fig. 4. Activation of IKK and MAP kinase cascades is not su⁄cient to activate IRF-3. A: U373/CD14 cells were mock-treated (lanes 1 and 5)
or treated with LPS (5 Wg/ml, lane 2), IL-1 (2 ng/ml, lane 3) or poly(I:C) (20 Wg/ml, lane 4) for 1 h, or irradiated with UV (3 mJ/cm2, lane 6;
30 mJ/cm2, lane 7). The cell extracts were prepared and subjected to native PAGE assay for IRF-3, EMSA for NF-UB, or immunoblotting for
phospho-speci¢c p38 and SAPK/JNK. B: Extracts from mock-treated (lane 1), UV-irradiated (30 mJ/cm2, lane 2) or poly(I:C)-treated cells
were subjected to EMSA using ISRE of ISG15 as probe. C: The same extracts used in B were subjected to SDS^PAGE followed by immuno-
blotting with anti-IRF-3.
Fig. 3. E¡ect of inhibitors on IRF-3 activation induced by LPS or poly(I:C). U373/CD14 cells were incubated in medium either with or with-
out inhibitors for 30 min, then LPS or poly(I:C) was added to the medium for 1 h as indicated. Cell extracts were subjected to native PAGE
assay and EMSA for IRF-3 and NF-UB activation, respectively. A: Cells mock-treated, lanes 1 and 10; cells treated with LPS, lanes 2^9; cells
treated with poly(I:C), lanes 11^18. Inhibitors: staurosporine (1 WM), lanes 3 and 12; TPCK (50 WM), lanes 4 and 13; TLCK (50 WM), lanes 5
and 14; PD98059 (10 WM), lanes 6 and 15; SB202190 (10 WM), lanes 7 and 16; hypericin (10 WM), lanes 8 and 17; calphostin (1 WM), lanes 9
and 18. Staurosporine alone activates NF-UB [16]. B: Cells mock-treated, lanes 1 and 6; cells treated with LPS, lanes 2^5; cells treated with
poly(I:C), lanes 7^10. Inhibitors: tilorone (10 WM), lanes 3 and 8; tilorone 874 (10 WM), lanes 4 and 9; acridine orange (10 WM), lanes 5 and
10. C: E¡ect of geldanamycin on IRF-3 activation. Cells were treated in the absence (lanes 2 and 6) or presence of geldanamycin: 5 WM, lanes
3 and 7; 10 WM, lanes 4 and 8; 25 WM, lanes 5 and 9. Cells mock-treated, lane 1; cells treated with LPS, lanes 2^5; cells treated with
poly(I:C), lanes 6^9.
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4. Discussion
We analyzed and compared the mechanism of IRF-3 acti-
vation induced by LPS and dsRNA. Apparently these stimuli
transmit signals via distinct receptors and distinct intracellular
pathways are activated. For example, geldanamycin speci¢-
cally inhibited signaling by dsRNA/virus but exhibited little
e¡ect on LPS signaling. Furthermore, our analysis demon-
strated that an alternative adapter to MyD88, TIRAP/
MAL, plays a critical role in LPS-induced but not dsRNA-
induced activation of IRF-3 (Fig. 5). A dsRNA-dependent
protein kinase, PKR, is implicated to function downstream
of TIRAP/MAL to activate NF-UB [15]. However, evidence
suggests that PKR is unlikely to be the kinase involved in the
activation of IRF-3 [21,22].
Recently, it was reported that TLR3-de¢cient macrophages
are hyporesponsive to poly(I:C) treatment and that overex-
pression of TLR3 in human 293 cells, which are virtually non-
responsive to poly(I:C) treatment, confers responsiveness to
dsRNA [23]. These results suggest that TLR3 functions as a
signaling receptor for free dsRNA. However, 293 cells are
e⁄ciently stimulated by infection with virus to produce NF-
UB and IRF-3 [8] (our unpublished observation). Also dsRNA
needs to be transfected to induce the expression of IFN in
rodent ¢broblasts [24]. These observations argue for a cyto-
plasmic receptor for dsRNA leading to the activation of NF-
UB and IRF-3.
The analyses demonstrated that IRF-3 underwent phos-
phorylation at speci¢c residues and an association with the
co-activator CBP/p300 after the treatment with LPS in a man-
ner indistinguishable from that induced by dsRNA/virus. We
hypothesize therefore that downstream of the signaling trig-
gered by LPS or dsRNA/virus, a common cascade, which is
sensitive to TPCK, is triggered to activate IRF-3 [16].
The IFN system, including IFN, its receptors, the signaling
machinery and IRFs, is limited to higher vertebrates, suggest-
ing that the system was acquired later in evolution to counter-
act viral infections or invasion by foreign nucleic acids. Inter-
estingly, the Toll and TLR system has been conserved during
evolution and, at least in Drosophila, functions as a defense
against bacterial infection [1,3]. Therefore, the IFN system
likely adopted the upstream cascade of the TLR system but
developed its own unique signaling pathways to combat not
only viral but bacterial infections.
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